Worldwide Monoclonal Antibodies Industry to 2033 - Rising mAb Therapy Applications for Targeted Therapies Drives Growth

News provided by

Jan 18, 2023, 12:30 ET

DUBLIN, Jan. 18, 2023 /PRNewswire/ -- The "Monoclonal Antibodies Market by Source Type, Production Type, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

The monoclonal antibodies market size is estimated to be USD 189,432 million in 2022 and is expected to witness a CAGR of 11.42% during the forecast period 2023-2033.

Increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and others, rising mAb therapy applications for targeted therapies and growing patient and physician knowledge of such therapies are factors contributing to the market growth.

Additionally, strategic initiatives performed by top companies for the development of mAb products and wide product launches and robust R&D for new product development is expected to propel the market growth. However, rising costs of mAb development and shortage of skilled workforce is expected to hinder the growth.

Strategic initiatives performed by top companies for the development of mAb products is expected to drive the market. For instance, Atlas Antibodies AB and T-Cure Bioscience, Inc. collaborated together to produce and supply CT83 mAbs in October 2021. Similar to this, Ono Pharmaceutical Co., Ltd. and Neurimmune AG partnered up to develop mAb medicines against new therapeutic targets for neurodegenerative diseases in January 2022.

Wide product launches and robust R&D for new product development is predicted to fuel the market growth. The potential for the monoclonal antibodies market to grow will be spurred by a strong emphasis on the research and development of novel monoclonal antibody therapeutics to provide highly targeted treatment for complex and severe diseases.

Industry participants will substantially benefit from government assistance and regulatory permits for the expansion of the monoclonal antibody business. For instance, the European Commission (EC) authorised Bristol Myers Squibb's OPDIVO and Yervoy combination therapy in June 2021 to treat patients with malignant pleural mesothelioma.

Competitor Insights

Some of the key players operating in the monoclonal antibodies market are GlaxoSmithKline plc, Merck & Co., Inc., Abbott Laboratories, Biogen Inc., AstraZeneca plc, Eli Lilly And Company, Novartis AG, Johnson & Johnson Services, Inc., Bayer AG, Amgen Inc., Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Pfizer Inc, Daiichi Sankyo Company, Limited, Thermo Fisher Scientific, Inc., Novo Nordisk A/S, Sanofi S.A., and Merck KGaA.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

For instance, Sanofi S.A. and Blackstone Life Sciences collaborated to develop a subcutaneous Sarclisa mAb formulation faster for the treatment of multiple myeloma patients in March 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including source type, production type, application, and end use from 2023 to 2033.

Market Segmentation:

Source (Revenue, USD Million), 2022 - 2033

Chimeric
Human
Murine
Humanized

Production Type (Revenue, USD Million), 2022 - 2033

In Vitro
In Vivo

Application (Revenue, USD Million), 2022 - 2033

Autoimmune Diseases
Oncology
Neurological Diseases
Infectious Diseases
Others

End Use (Revenue, USD Million), 2022 - 2033

Specialty Centres
Hospitals
Others

By Region (Revenue, USD Million), 2022 - 2033

North America

U.S
Canada

Europe

Germany
France
UK
Spain
Italy
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of APAC

Latin America

Brazil
Mexico
Argentina
Rest of LATAM

Middle East & Africa

South Africa
GCC
Rest of MEA

Companies Mentioned

GlaxoSmithKline plc
Merck & Co. Inc.
Abbott Laboratories
Biogen Inc.
AstraZeneca plc
Eli Lilly And Company
Novartis AG
Johnson & Johnson Services Inc.
Bayer AG
Amgen Inc.
Bristol Myers Squibb
F. Hoffman-La Roche Ltd.
Viatris Inc.
Pfizer Inc
Daiichi Sankyo Company
Limited
Thermo Fisher Scientific Inc.
Novo Nordisk A/S
Sanofi S.A.
Merck KGaA

For more information about this report visit https://www.researchandmarkets.com/r/ovymzx

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets